ClinicalTrials.gg
CompletedNCT01937871Updated Jun 20, 2017Results posted

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)

A Phase 3 interventional study of 5 mg Tadalafil and Placebo in Benign Prostate Hyperplasia and Erectile Dysfunction, sponsored by Eli Lilly and Company. Completed at 14 sites in China. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2017-06-20.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
909
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies testing tadalafil in Prostatic Hyperplasia — 2 open to participants now, 2 under way, none of them phase 3. Tadalafil · Prostatic Hyperplasia.

Enrollment
2nd of 26
909 · median 258
Started
2013
with 1 other
Phase 3
10 of 26
none open now
Registered
15th of 26
by date
Lead sponsor
16 of 26
Eli Lilly and Company

Among the 26 studies testing tadalafil in Prostatic Hyperplasia, this one is the 2nd largest by enrollment, is one of 2 that started in 2013, is one of 10 in phase 3, and was the 15th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

2 of the 26 studies testing tadalafil in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About tadalafil

Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing tadalafil in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

The purpose of this study is to see whether tadalafil can reduce the signs and symptoms in men with Erectile Dysfunction (ED) and Benign Prostatic Hyperplasia-Lower Urinary Tract Symptoms (BPH-LUTS) and improve their quality of life.

03

Conditions studied

  • Benign Prostate Hyperplasia
  • Erectile Dysfunction
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Present with a history of ED and signs and symptoms of BPH.
  • Are sexually active with an adult female partner, and expect to remain sexually active with the same adult female partner for the duration of the study.

Main Exclusion Criteria:

  • Current treatment with nitrates.
  • Prostate-specific antigen (PSA) greater than 10.0 nanogram (ng)/mL at 1st screening.
  • PSA greater than or equal to 4.0 to less than or equal to 10.0 ng/mL at 1st screening if prostate has not been ruled out to the satisfaction of a urologist
  • Suffering from other urinary disease like cancer, or infection
  • Serious cardiovascular disease
  • History of significant renal insufficiency
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
909 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo matching tadalafil or tamsulosin administered once daily by mouth for 16 weeks.

    Drug: Placebo

  • Experimental
    5 mg Tadalafil

    Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period. Tadalafil 5 milligram (mg) tablet administered once daily by mouth for 12 weeks during the double-blind treatment period

    Drug: 5 mg Tadalafil · Drug: Placebo

  • Other
    0.2 mg Tamsulosin

    Placebo administered once daily by mouth for 4 weeks during the single-blind placebo run-in period. Tamsulosin 0.2 mg capsule administered once daily by mouth for 12 weeks during the double-blind treatment period

    Drug: Placebo · Drug: 0.2 mg Tamsulosin

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12

    IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question was scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM).The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline Erectile dysfunction (ED) severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment.The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at Week 12

    IIEF is a 15 item self-reported questionnaire to assess overall erectile function and satisfaction during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0(low/no erectile function) to 5(high erectile function) and Question 15 is scored 1(very low confidence) to 5(very high confidence) with a total score ranging from 1 to 30.Higher scores represent better erectile function.LS mean of change from baseline to endpoint is from MMRM.The model includes effects for treatment,country/region,baseline lower urinary tract symptoms(LUTS) severity (moderate/severe),visit,treatment-by-visit interaction,centered baseline value(defined as the baseline value for a participant-the overall baseline mean value), placebo lead-in total IPSS change(change from Visit 2 at Visit 3),centered baseline-by-treatment and treatment-by-country/region interactions.The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

    Time frame: Baseline, Week 12

  2. Change From Baseline in Yes Responses to Question 2 of the Sexual Encounter Profile (SEP) Questionnaire at Week 12

    Participant-assessed diary assesses the mean change from baseline in the percentage of "yes" responses to SEP Q2, "Were you able to insert your penis into your partner's vagina?". The SEP Q2 score was determined as the percentage of "yes" responses to SEP Q2 out of all sexual attempts recorded during the time period. Change is defined as the percentage of "yes" responses at endpoint minus the percentage of "yes" responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p \>= 0.10.

    Time frame: Baseline, Week 12

  3. Change From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 12

    Participant-assessed diary assesses the mean change from baseline in the percentage of "yes" responses to SEP Q3, "Did your erection last long enough for you to have successful intercourse?".The SEP Q3 score is determined as the percentage of "yes" responses to SEP Q3 out of all sexual attempts recorded during the time period. Change was defined as the percentage of "yes" responses at endpoint minus percentage of "yes" responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p \>= 0.10.

    Time frame: Baseline, Week 12

  4. Change From Baseline in IPSS at Week 12

    IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question is scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM).The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline Erectile dysfunction (ED) severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment. The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

    Time frame: Baseline, Week 12

  5. Change From Baseline in Uroflowmetry Measures at Week 12

    Qmax is defined as the peak urine flow rate (measured in milliliters per second \[mL/sec\] using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 milliliters (mL) and the voided volume (Vcomp) was \>=125 mL. Changes in Qmax from baseline to endpoint in the double-blind treatment period were analyzed using Type III sums of squares ANOVA on rank-transformed data with a term for treatment group.

    Time frame: Baseline, Week 12

  6. Change From Baseline in Postvoid Residual Volume (PVR) at Week 12

    The amount of urine remaining in the bladder after void completion.

    Time frame: Baseline, Week 12

  7. Change From Baseline in IPSS Storage (Irritative) Subscore at Week 12

    IPSS Storage (Irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores ranged from 0 (no irritative symptoms) to 5 (frequent irritative symptoms), with total subscore of the 3 questions for irritative subscore ranging from 0 to 15; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline ED severity (mild/moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions.

    Time frame: Baseline, Week 12

  8. Change From Baseline in IPSS Voiding (Obstructive) Subscore at Week 12

    IPSS voiding (obstructive) subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores ranged from 0 (no obstructive symptoms) to 5 (frequent obstructive symptoms), with total subscore of the 4 questions of the obstructive score ranging from 0 to 20; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline ED severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions.

    Time frame: Baseline, Week 12

  9. Change From Baseline in IPSS Quality of Life (QoL) Index at Week 12

    IPSS QoL assess participant response to the following question:"If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?". Response options are Delighted(0),Pleased(1);Mostly satisfied(2);mixed about equally satisfied and dissatisfied(3);Mostly dissatisfied(4);Unhappy(5);Terrible(6),with a total ranging from 0 to 6; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares(LS) mean of change from baseline(bl) to endpoint is from MMRM.The model includes effects for treatment,country/region, prior alpha-blocker therapy,baseline ED severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered bl value (defined as the bl value for a participant -the overall bl mean value),placebo lead-in total IPSS change(change from Visit 2 at Visit 3),centered bl-by-treatment and treatment-by-country/region interactions.

    Time frame: Baseline, Week 12

  10. Number of Participants With Patient Global Impression of Improvement (PGI-I) at Week 12

    PGI-I measures a participant's perception of improvement at the time of assessment compared with the start of treatment. Score ranges from 1 (very much better) to 7 (very much worse).

    Time frame: Week 12

  11. Number of Participants With Clinician Global Impression of Improvement (CGI-I) at Week 12

    CGI-I measures clinician's perception of participant improvement at the time of assessment (compared with the start of treatment) with scores ranging from 1 (very much better) to 7 (very much worse).

    Time frame: Week 12

  12. Change From Baseline in IIEF Overall Satisfaction (OS) at Week 12

    IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF-OS is the sum of Questions 13 and 14. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each question, with a total subscore ranging from 2 to 10;higher scores represent better erectile function. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction,centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

    Time frame: Baseline, Week 12

  13. Change From Baseline in IIEF Intercourse Satisfaction at Week 12

    IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF-IS is the sum of Questions 6,7 and 8 of the IIEF. Scores range from 0(low/no satisfaction) to 5(high satisfaction) for each question, with the total possible score for the 3 questions ranging from 0 to 15.Higher scores were indicative of an increase in intercourse satisfaction. Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction,centered baseline value(defined as the baseline value for a participant- the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

    Time frame: Baseline, Week 12

  14. Change From Baseline in IIEF Orgasmic Function at Week 12

    IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF orgasmic function is the sum of Q9 and Q10 of the IIEF. Scores ranged from 0 (no stimulation) to 5 (almost always) for each question, with the total possible score for the 2 questions ranging from 0 to 10. Higher scores were indicative of better orgasmic function. Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

    Time frame: Baseline, Week 12

  15. Change From Baseline in IIEF Sexual Desire at Week 12

    IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF sexual desire is the sum of Q11 and Q12. Scores ranged from 1 (low/almost never) to 5 (very high/almost always) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Higher scores were indicative of increased sexual desire. Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

    Time frame: Baseline, Week 12

  16. Change From Baseline in IIEF Subscores at Week 12

    IIEF Question 3 asks how often a participant was able to penetrate his partner over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). IIEF Question 4 asks whether/how often a participant was able to maintain an erection after penetration over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

    Time frame: Baseline, Week 12

  17. Change From Baseline in Total IPSS at Week 4 and Week 8

    IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question is scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline ED severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment. The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

    Time frame: Baseline, Week 4; Baseline, Week 8

  18. Change From Baseline in IIEF EF at Week 4 and Week 8

    IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 were scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 was scored 1 (very low confidence) to 5 (very high confidence) with a total score ranging from 1 to 30. Higher scores represent better erectile function. LS mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

    Time frame: Baseline, Week 4; Baseline, Week 8

  19. Change From Baseline in Yes Responses to Question 2 of the SEP Questionnaire at Week 4 and Week 8

    Participant-assessed diary assesses the mean change from baseline in the percentage of "yes" responses to SEP Q2, "Were you able to insert your penis into your partner's vagina?". The SEP Q2 score is determined as the percentage of "yes" responses to SEP Q2 out of all sexual attempts recorded during the time period. Change was defined as the percentage of "yes" responses at endpoint minus the percentage of "yes" responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p \>= 0.10.

    Time frame: Baseline, Week 4; Baseline, Week 8

  20. Change From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 4 and Week 8

    Participant-assessed diary assesses the mean change from baseline in the percentage of "yes" responses to SEP Q3, "Did your erection last long enough for you to have successful intercourse?". The SEP Q3 score is determined as the percentage of "yes" responses to SEP Q3 out of all sexual attempts recorded during the time period. Change was defined as the percentage of "yes" responses at endpoint minus percentage of "yes" responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p \>= 0.10.

    Time frame: Baseline, Week 4; Baseline, Week 8

  21. Change From Baseline in Modified International Prostate Symptom Score (mIPSS) at Week 2

    The modified IPSS is the total IPSS collected at 2 weeks post-baseline.The total IPSS is obtained by combining the scores of the responses to component questions 1 through 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from ANCOVA. The model includes terms for treatment, country/region, prior alpha-blocker use and baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p \>= 0.10.

    Time frame: Baseline, Week 2

07

Results

Posted Feb 7, 2017

Participant flow

Participant flow — Overall Study
MilestonePlacebo5 mg Tadalafil0.2 mg Tamsulosin
Started361363185
Received at least one dose of study drug361362185
Completed337346174
Not completed241711
Withdrew: Adverse event662
Withdrew: Lost to follow-up824
Withdrew: Withdrawal by subject964
Withdrew: Physician decision010
Withdrew: Entry criteria not met121

Outcome measures

PrimaryChange From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12

IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question was scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM).The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline Erectile dysfunction (ED) severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment.The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12
units on a scalePlacebo5 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12-4.08 ± 0.402-5.49 ± 0.395-4.92 ± 0.493
Statistical analysis
  • Placebo vs 5 mg Tadalafil · Mean difference (final values): -1.41 · 95% CI -2.25 to -0.57
SecondaryChange From Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at Week 12

IIEF is a 15 item self-reported questionnaire to assess overall erectile function and satisfaction during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 are scored 0(low/no erectile function) to 5(high erectile function) and Question 15 is scored 1(very low confidence) to 5(very high confidence) with a total score ranging from 1 to 30.Higher scores represent better erectile function.LS mean of change from baseline to endpoint is from MMRM.The model includes effects for treatment,country/region,baseline lower urinary tract symptoms(LUTS) severity (moderate/severe),visit,treatment-by-visit interaction,centered baseline value(defined as the baseline value for a participant-the overall baseline mean value), placebo lead-in total IPSS change(change from Visit 2 at Visit 3),centered baseline-by-treatment and treatment-by-country/region interactions.The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at Week 12
units on a scalePlacebo5 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in International Index of Erectile Function (IIEF) Erectile Function (EF) Domain at Week 121.88 ± 0.4485.24 ± 0.4392.64 ± 0.556
SecondaryChange From Baseline in Yes Responses to Question 2 of the Sexual Encounter Profile (SEP) Questionnaire at Week 12

Participant-assessed diary assesses the mean change from baseline in the percentage of "yes" responses to SEP Q2, "Were you able to insert your penis into your partner's vagina?". The SEP Q2 score was determined as the percentage of "yes" responses to SEP Q2 out of all sexual attempts recorded during the time period. Change is defined as the percentage of "yes" responses at endpoint minus the percentage of "yes" responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p \>= 0.10.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percentage of "yes" responses
Change From Baseline in Yes Responses to Question 2 of the Sexual Encounter Profile (SEP) Questionnaire at Week 12
percentage of "yes" responsesPlacebo5 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in Yes Responses to Question 2 of the Sexual Encounter Profile (SEP) Questionnaire at Week 1210.90 ± 2.61823.87 ± 2.5486.84 ± 3.074
SecondaryChange From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 12

Participant-assessed diary assesses the mean change from baseline in the percentage of "yes" responses to SEP Q3, "Did your erection last long enough for you to have successful intercourse?".The SEP Q3 score is determined as the percentage of "yes" responses to SEP Q3 out of all sexual attempts recorded during the time period. Change was defined as the percentage of "yes" responses at endpoint minus percentage of "yes" responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p \>= 0.10.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · percentage of "yes" responses
Change From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 12
percentage of "yes" responsesPlacebo5 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 1215.96 ± 3.01636.62 ± 2.93517.42 ± 3.557
SecondaryChange From Baseline in IPSS at Week 12

IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question is scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM).The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline Erectile dysfunction (ED) severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment. The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in IPSS at Week 12
units on a scalePlacebo5 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in IPSS at Week 12-4.08 ± 0.402-5.49 ± 0.395-4.92 ± 0.493
Statistical analysis
  • Placebo vs 0.2 mg Tamsulosin · Mean difference (final values): -0.85 · 95% CI -1.87 to 0.18
SecondaryChange From Baseline in Uroflowmetry Measures at Week 12

Qmax is defined as the peak urine flow rate (measured in milliliters per second \[mL/sec\] using standard calibrated flowmeter). At each visit, a uroflowmetry assessment was considered valid and the data were included only if the prevoid total bladder volume (assessed by ultrasound) was \>=150 to \<=550 milliliters (mL) and the voided volume (Vcomp) was \>=125 mL. Changes in Qmax from baseline to endpoint in the double-blind treatment period were analyzed using Type III sums of squares ANOVA on rank-transformed data with a term for treatment group.

Time frame:
Baseline, Week 12
Reported as:
Mean · Milliliters/seconds (mL/sec)
Change From Baseline in Uroflowmetry Measures at Week 12
Milliliters/seconds (mL/sec)Placebo5 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in Uroflowmetry Measures at Week 121.5 ± 5.461.9 ± 5.682.0 ± 5.37
SecondaryChange From Baseline in Postvoid Residual Volume (PVR) at Week 12

The amount of urine remaining in the bladder after void completion.

Time frame:
Baseline, Week 12
Reported as:
Mean · milliliters (mL)
Change From Baseline in Postvoid Residual Volume (PVR) at Week 12
milliliters (mL)Placebo5 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in Postvoid Residual Volume (PVR) at Week 12-6.3 ± 47.86-3.8 ± 49.02-9.5 ± 44.76
SecondaryChange From Baseline in IPSS Storage (Irritative) Subscore at Week 12

IPSS Storage (Irritative) subscore is the sum of Questions 2, 4 and 7 of the IPSS questionnaire. Scores ranged from 0 (no irritative symptoms) to 5 (frequent irritative symptoms), with total subscore of the 3 questions for irritative subscore ranging from 0 to 15; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline ED severity (mild/moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in IPSS Storage (Irritative) Subscore at Week 12
units on a scalePlacebo5 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in IPSS Storage (Irritative) Subscore at Week 12-1.68 ± 0.176-2.01 ± 0.173-1.90 ± 0.215
SecondaryChange From Baseline in IPSS Voiding (Obstructive) Subscore at Week 12

IPSS voiding (obstructive) subscore is the sum of Questions 1, 3, 5 and 6 of the IPSS questionnaire. Scores ranged from 0 (no obstructive symptoms) to 5 (frequent obstructive symptoms), with total subscore of the 4 questions of the obstructive score ranging from 0 to 20; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline ED severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in IPSS Voiding (Obstructive) Subscore at Week 12
units on a scalePlacebo5 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in IPSS Voiding (Obstructive) Subscore at Week 12-2.42 ± 0.271-3.49 ± 0.266-3.07 ± 0.331
SecondaryChange From Baseline in IPSS Quality of Life (QoL) Index at Week 12

IPSS QoL assess participant response to the following question:"If you were to spend the rest of your life with your urinary condition just the way it is now, how would you feel about that?". Response options are Delighted(0),Pleased(1);Mostly satisfied(2);mixed about equally satisfied and dissatisfied(3);Mostly dissatisfied(4);Unhappy(5);Terrible(6),with a total ranging from 0 to 6; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares(LS) mean of change from baseline(bl) to endpoint is from MMRM.The model includes effects for treatment,country/region, prior alpha-blocker therapy,baseline ED severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered bl value (defined as the bl value for a participant -the overall bl mean value),placebo lead-in total IPSS change(change from Visit 2 at Visit 3),centered bl-by-treatment and treatment-by-country/region interactions.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in IPSS Quality of Life (QoL) Index at Week 12
units on a scalePlacebo5 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in IPSS Quality of Life (QoL) Index at Week 12-0.85 ± 0.099-0.98 ± 0.097-1.00 ± 0.121
SecondaryNumber of Participants With Patient Global Impression of Improvement (PGI-I) at Week 12

PGI-I measures a participant's perception of improvement at the time of assessment compared with the start of treatment. Score ranges from 1 (very much better) to 7 (very much worse).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants With Patient Global Impression of Improvement (PGI-I) at Week 12
ParticipantsPlacebo5 mg Tadalafil0.2 mg Tamsulosin
Very Much Worse000
Much Worse320
A Little Worse521
No Change875337
A Little Better16916493
Much Better7311939
Very Much Better5136
SecondaryNumber of Participants With Clinician Global Impression of Improvement (CGI-I) at Week 12

CGI-I measures clinician's perception of participant improvement at the time of assessment (compared with the start of treatment) with scores ranging from 1 (very much better) to 7 (very much worse).

Time frame:
Week 12
Reported as:
Count of participants · Participants
Number of Participants With Clinician Global Impression of Improvement (CGI-I) at Week 12
ParticipantsPlacebo5 mg Tadalafil0.2 mg Tamsulosin
Very Much Worse010
Much Worse200
A Little Worse1251
No Change916639
A Little Better13014085
Much Better9212041
Very Much Better162110
SecondaryChange From Baseline in IIEF Overall Satisfaction (OS) at Week 12

IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF-OS is the sum of Questions 13 and 14. Scores range from 1 (low/no satisfaction) to 5 (high satisfaction) for each question, with a total subscore ranging from 2 to 10;higher scores represent better erectile function. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction,centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in IIEF Overall Satisfaction (OS) at Week 12
units on a scalePlacebo5 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in IIEF Overall Satisfaction (OS) at Week 120.62 ± 0.1201.54 ± 0.1180.71 ± 0.150
SecondaryChange From Baseline in IIEF Intercourse Satisfaction at Week 12

IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF-IS is the sum of Questions 6,7 and 8 of the IIEF. Scores range from 0(low/no satisfaction) to 5(high satisfaction) for each question, with the total possible score for the 3 questions ranging from 0 to 15.Higher scores were indicative of an increase in intercourse satisfaction. Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction,centered baseline value(defined as the baseline value for a participant- the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in IIEF Intercourse Satisfaction at Week 12
units on a scalePlacebo5 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in IIEF Intercourse Satisfaction at Week 12-0.05 ± 0.1831.08 ± 0.1790.41 ± 0.227
SecondaryChange From Baseline in IIEF Orgasmic Function at Week 12

IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF orgasmic function is the sum of Q9 and Q10 of the IIEF. Scores ranged from 0 (no stimulation) to 5 (almost always) for each question, with the total possible score for the 2 questions ranging from 0 to 10. Higher scores were indicative of better orgasmic function. Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in IIEF Orgasmic Function at Week 12
units on a scalePlacebo5 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in IIEF Orgasmic Function at Week 120.28 ± 0.1691.31 ± 0.1650.57 ± 0.207
SecondaryChange From Baseline in IIEF Sexual Desire at Week 12

IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF sexual desire is the sum of Q11 and Q12. Scores ranged from 1 (low/almost never) to 5 (very high/almost always) for each question, with the total possible score for the 2 questions ranging from 2 to 10. Higher scores were indicative of increased sexual desire. Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in IIEF Sexual Desire at Week 12
units on a scalePlacebo5 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in IIEF Sexual Desire at Week 120.46 ± 0.1141.12 ± 0.1110.28 ± 0.142
SecondaryChange From Baseline in IIEF Subscores at Week 12

IIEF Question 3 asks how often a participant was able to penetrate his partner over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). IIEF Question 4 asks whether/how often a participant was able to maintain an erection after penetration over the past 4 weeks. Scores range from 0 (did not attempt intercourse) to 5 (almost always or always). Least squares (LS) mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in IIEF Subscores at Week 12
units on a scalePlacebo5 mg Tadalafil0.2 mg Tamsulosin
IIEF Question 30.28 ± 0.0970.87 ± 0.0950.39 ± 0.120
IIEF Question 40.30 ± 0.0930.87 ± 0.0910.50 ± 0.115
SecondaryChange From Baseline in Total IPSS at Week 4 and Week 8

IPSS Total Score is the sum of Questions 1 through 7 of the IPSS questionnaire. Each question is scored from 0 (none/no symptoms) to 5 (frequent symptoms) for an IPSS Total Score ranging from 0 to 35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from an analysis mixed model for repeated measures (MMRM). The model includes effects for treatment, country/region, prior alpha-blocker therapy, baseline ED severity (mild/moderate/severe),visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment. The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

Time frame:
Baseline, Week 4; Baseline, Week 8
Reported as:
Least squares mean · units on a scale
Change From Baseline in Total IPSS at Week 4 and Week 8
units on a scalePlacebo5 mg Tadalafil0.2 mg Tamsulosin
Week 4-2.99 ± 0.365-4.10 ± 0.359-3.92 ± 0.434
Week 8-3.50 ± 0.385-4.85 ± 0.378-4.44 ± 0.465
SecondaryChange From Baseline in IIEF EF at Week 4 and Week 8

IIEF is a 15 item self-reported questionnaire used to assess overall erectile function and satisfaction during the past 4 weeks. IIEF- EF is the sum of Questions 1-5 and 15 of the IIEF. Questions 1-5 were scored 0 (low/no erectile function) to 5 (high erectile function) and Question 15 was scored 1 (very low confidence) to 5 (very high confidence) with a total score ranging from 1 to 30. Higher scores represent better erectile function. LS mean of change from baseline to endpoint is from MMRM. The model includes effects for treatment, country/region, baseline LUTS severity (moderate/severe), visit, treatment-by-visit interaction, centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), centered baseline-by-treatment and treatment-by-country/region interactions. The centered baseline-by-treatment and treatment-by-country interactions was removed if p \>= 0.10.

Time frame:
Baseline, Week 4; Baseline, Week 8
Reported as:
Least squares mean · units on a scale
Change From Baseline in IIEF EF at Week 4 and Week 8
units on a scalePlacebo5 mg Tadalafil0.2 mg Tamsulosin
Week 41.23 ± 0.4124.50 ± 0.4031.43 ± 0.498
Week 81.51 ± 0.4234.77 ± 0.4142.19 ± 0.516
SecondaryChange From Baseline in Yes Responses to Question 2 of the SEP Questionnaire at Week 4 and Week 8

Participant-assessed diary assesses the mean change from baseline in the percentage of "yes" responses to SEP Q2, "Were you able to insert your penis into your partner's vagina?". The SEP Q2 score is determined as the percentage of "yes" responses to SEP Q2 out of all sexual attempts recorded during the time period. Change was defined as the percentage of "yes" responses at endpoint minus the percentage of "yes" responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p \>= 0.10.

Time frame:
Baseline, Week 4; Baseline, Week 8
Reported as:
Least squares mean · percentage of "yes" responses
Change From Baseline in Yes Responses to Question 2 of the SEP Questionnaire at Week 4 and Week 8
percentage of "yes" responsesPlacebo5 mg Tadalafil0.2 mg Tamsulosin
Week 45.43 ± 2.39420.53 ± 2.3256.21 ± 2.827
Week 810.79 ± 2.51023.22 ± 2.4417.42 ± 2.950
SecondaryChange From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 4 and Week 8

Participant-assessed diary assesses the mean change from baseline in the percentage of "yes" responses to SEP Q3, "Did your erection last long enough for you to have successful intercourse?". The SEP Q3 score is determined as the percentage of "yes" responses to SEP Q3 out of all sexual attempts recorded during the time period. Change was defined as the percentage of "yes" responses at endpoint minus percentage of "yes" responses at baseline. Least squares (LS) mean of change from baseline to endpoint is from an analysis of covariance (ANCOVA). The model includes terms for treatment, country/region, baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p \>= 0.10.

Time frame:
Baseline, Week 4; Baseline, Week 8
Reported as:
Least squares mean · percentage of "yes" responses
Change From Baseline in Yes Responses to Question 3 of the SEP Questionnaire at Week 4 and Week 8
percentage of "yes" responsesPlacebo5 mg Tadalafil0.2 mg Tamsulosin
Week 47.41 ± 2.70123.38 ± 2.6229.57 ± 3.213
Week 814.08 ± 2.88432.27 ± 2.80514.98 ± 3.411
SecondaryChange From Baseline in Modified International Prostate Symptom Score (mIPSS) at Week 2

The modified IPSS is the total IPSS collected at 2 weeks post-baseline.The total IPSS is obtained by combining the scores of the responses to component questions 1 through 7. Each question is scored from 0-5 for a total IPSS range of 0-35 points; higher numerical scores from the IPSS questionnaire represent greater severity of symptoms. Least squares (LS) mean of change from baseline to endpoint is from ANCOVA. The model includes terms for treatment, country/region, prior alpha-blocker use and baseline ED severity (mild/moderate/severe), centered baseline value (defined as the baseline value for a participant - the overall baseline mean value), placebo lead-in total IPSS change (change from Visit 2 at Visit 3), the centered baseline-by-treatment and the treatment-by-country/region interactions. The interaction terms are removed if p \>= 0.10.

Time frame:
Baseline, Week 2
Reported as:
Least squares mean · units on a scale
Change From Baseline in Modified International Prostate Symptom Score (mIPSS) at Week 2
units on a scalePlacebo5 mg Tadalafil0.2 mg Tamsulosin
Change From Baseline in Modified International Prostate Symptom Score (mIPSS) at Week 2-2.19 ± 0.342-3.40 ± 0.336-3.20 ± 0.403

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—5/361 (1.4%)62/361 (17.2%)
5 mg Tadalafil—7/362 (1.9%)64/362 (17.7%)
0.2 mg Tamsulosin—2/185 (1.1%)21/185 (11.4%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventPlacebo5 mg Tadalafil0.2 mg Tamsulosin
Melanosis coliGastrointestinal disorders0/3610/3621/185
Colon adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3610/3621/185
Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3610/3621/185
Acute myocardial infarctionCardiac disorders1/3610/3620/185
Inguinal herniaGastrointestinal disorders1/3610/3620/185
Rectal polypGastrointestinal disorders1/3610/3620/185
Benign prostatic hyperplasiaReproductive system and breast disorders1/3610/3620/185
Peripheral arterial occlusive diseaseVascular disorders1/3610/3620/185
Coronary artery diseaseCardiac disorders0/3611/3620/185
Lung infectionInfections and infestations0/3611/3620/185
Most frequent other events
Showing 10 of 116
Most frequent other events
EventPlacebo5 mg Tadalafil0.2 mg Tamsulosin
DizzinessNervous system disorders6/3613/3625/185
NasopharyngitisInfections and infestations5/3618/3622/185
Back painMusculoskeletal and connective tissue disorders0/3616/3620/185
Blood creatine phosphokinase increasedInvestigations3/3615/3621/185
Upper respiratory tract infectionInfections and infestations2/3614/3620/185
CoughRespiratory, thoracic and mediastinal disorders2/3614/3621/185
Urinary tract infectionInfections and infestations1/3611/3622/185
Abdominal pain upperGastrointestinal disorders3/3610/3620/185
HypertensionVascular disorders3/3610/3621/185
MyalgiaMusculoskeletal and connective tissue disorders1/3613/3620/185

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)Placebo5 mg Tadalafil0.2 mg TamsulosinTotal
Mean61.8 ± 7.3561.8 ± 7.2761.9 ± 7.0661.8 ± 7.25
Sex: Female, Male
Sex: Female, Male(Participants)Placebo5 mg Tadalafil0.2 mg TamsulosinTotal
Female0000
Male361363185909
Region of Enrollment
Region of Enrollment(Participants)Placebo5 mg Tadalafil0.2 mg TamsulosinTotal
China279277143699
Korea, Republic of717135177
Taiwan1115733
08

Study locations

14 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Beijing, 100020, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changchun, 130021, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Changsha, 410011, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chengdu, 610072, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chongqing, 400038, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hangzhou, 310003, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hefei, 230022, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nanchang, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nanjing, 210008, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Shanghai, 200040, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Suzhou, 215006, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wenzhou, 325035, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Wu Han, 430030, China
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Xi'An, 710004, China
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2013
First posted
Sep 10, 2013
Start
Sep 2013
Primary completionActual
Dec 2015
CompletionActual
Dec 2015
Results first posted
Feb 7, 2017
Last update
Jun 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01937871
Responsible party
Sponsor
First posted
Sep 10, 2013
Start date
Sep 2013
Primary completion
Dec 2015
Completion
Dec 2015
Results posted
Feb 7, 2017
Last update
Jun 20, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tadalafil

Start the discussion